Evidence map›Paper›PMID 33543288›Full record

ArticleMolecular human reproduction2021

Use of selective PGE2 receptor antagonists on human endometriotic stromal cells and peritoneal macrophages.

Tomoko Makabe, Kaori Koga, Hiroshi Nagabukuro, Mari Asada, Erina Satake, Ayumi Taguchi, Arisa Takeuchi, Mariko Miyashita, Miyuki Harada, Tetsuya Hirata and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular human reproduction, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. New Potential Pharmacological Options for Endometriosis Associated Pain.International journal of molecular sciences · 2024
    Review
  7. Changing prostaglandin E2 (PGEReproductive medicine and biology · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Tomoko MakabeDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Kaori KogaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Hiroshi NagabukuroExtra Value Generation Drug Discovery Unit, Takeda Pharmaceutical Company, Fujisawa, Kanagawa 251-8555, Japan.
Mari AsadaExtra Value Generation Drug Discovery Unit, Takeda Pharmaceutical Company, Fujisawa, Kanagawa 251-8555, Japan.
Erina SatakeDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Ayumi TaguchiDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Arisa TakeuchiDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Mariko MiyashitaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Miyuki HaradaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Tetsuya HirataDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Yasushi HirotaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Osamu Wada-HiraikeDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Tomoyuki FujiiDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
Yutaka OsugaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113-8655, Japan.
The University of Tokyo · JPTakeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-hormonal therapeutic strategies for endometriosis are needed. The aim of this study was to characterize the effects of prostaglandin (PG)E2 receptor inhibitors to explore their potential as novel therapeutic strategies for endometriosis. The expression of PGE2 receptors (EP2 and EP4) in donated tissues from human ovarian endometriosis, adenomyosis and peritoneal endometriosis was examined using immunohistochemistry. Human endometriotic stromal cells (ESC) isolated from ovarian endometriotic tissue and peritoneal macrophages were treated with EP2 and EP4 antagonists. cAMP accumulation and the effect of EP antagonists were measured using cAMP assays. DNA synthesis in ESC was detected using bromodeoxyuridine incorporation analysis. Interleukin (IL)-6 and IL-8 protein levels in ESC supernatants were measured using ELISAs. mRNA expression level for aromatase by ESC, and selected cytokines by peritoneal macrophages was measured using RT-PCR. EP2 and EP4 receptors were expressed in cells derived from control and diseased tissue, ovarian endometriotic, adenomyotic and peritoneal lesions. A selective EP2 antagonist reduced DNA synthesis, cAMP accumulation and IL-1β-induced proinflammatory cytokine secretion and aromatase expression. A selective EP4 antagonist negated IL-1β-induced IL-6 secretion and aromatase expression. In peritoneal macrophages, EP expression was elevated in endometriosis samples but the EP4 antagonist reduced cAMP levels and expression of vascular endothelial growth factor, chemokine ligand 2 and chemokine ligand 3 mRNA. EP2 and EP4 are functioning in endometriosis lesions and peritoneal macrophages, and their selective antagonists can reduce EP-mediated actions, therefore, the EP antagonists are potential therapeutic agents for controlling endometriosis.

Indexed as

AdultAzetidinesBenzamidesCells, CulturedChemokinesCyclic AMPDNA ReplicationEndometriosisEndometriumFemaleHumansMacrophages, PeritonealProtein BiosynthesisReal-Time Polymerase Chain ReactionReceptors, ProstaglandinReceptors, Prostaglandin E, EP2 Subtype1-(4-fluorobenzoyl)-3-(((6-methoxy-2-naphthyl)oxy)methyl)azetidine-3-carboxylic acidAzetidinesBenzamidesChemokinesCyclic AMPReceptors, ProstaglandinReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 Subtype(S)-4-(1-(5-chloro-2-(4-fluorophenyoxy) benzamido)ethyl) benzoic acidadenomyosischemokineendometriosisinterleukinmacrophagesovaryperitoneumprostaglandin E2stromal cellsvascular endothelial growth factor

Identifiers

PMID33543288
PMCPMC7846198
OpenAlexW3108501232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.